Screening, prevalence, and burden of chronic kidney disease in people with type 2 diabetes managed by endocrinologists: A nationwide cross-sectional study
Authors' conclusion
CKD was highly prevalent in people with T2D managed by endocrinologists. Despite the high presence of comorbidities and medication use, we observed an important lack of screening and proper CKD identification.
Study context
- Population
- People with T2D with ≥1 visit with an endocrinologist at or after T2D diagnosis; cross-sectional analysis at index date 30th November 2023
- Participants
- 19,709 people
- Outcome
- CKD prevalence (CKD diagnosis code, or one estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m², or one UACR ≥30 mg/g)
- Follow-up
- Index date 30th November 2023
Methodological detailsnationwide, observational, secondary data from electronic health records (EHRs) (Telotron® database)
- Nationwide
- Observational
- Secondary data from EHRs (Telotron® database)
Main finding
As reported in the abstract
CKD prevalence
Chronic kidney disease (CKD) prevalence
40.7%
Patients with CKD without a CKD diagnosis code
54%
Observational data: associations, not effects.
Further findings
Urine albumin-to-creatinine ratio (UACR) screening · year prior to the index date
- T2D population without any registered UACR value
- 56.5%
Burden in T2D and CKD
- High prevalence of hypertension, hyperlipidemia and HF, and high rates of medication use
Original publication
Screening, prevalence, and burden of chronic kidney disease in people with type 2 diabetes managed by endocrinologists: A nationwide cross-sectional study. Diabetes Res Clin Pract. Published 19 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →